Paper Details

  1. Home
  2. Paper Details

Lymphoblastoid interferon therapy of chronic HBV infection. A comparison of 12 vs. 24 weeks of thrice weekly treatment.

Author: KarayiannisP, McDonaldJ A, ScullyL J, SheinR, ThomasH C

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of 40 patients with chronic hepatitis B infection compared 12-week and 24-week courses of interferon treatment. While both treatment durations were effective in 59% of male patients, the 24-week course was poorly tolerated and no more effective than the 12-week course. No female patients responded to treatment. Factors associated with a positive response included high AST levels, short duration of illness, and a history of acute hepatitis. The study concluded that a 12-week course of interferon is effective in some patients with chronic hepatitis B, but tolerability and individual patient characteristics should be considered.
Paper Details　
Original Abstract of the Article :
This study set out to examine the relative effectiveness and tolerability of 12- versus 24-week courses of thrice weekly intramuscular lymphoblastoid interferon in the treatment of hepatitis B 'e' antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection, and to identify pretreatment factor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0168-8278(87)80061-2

データ提供：米国国立医学図書館（NLM）

Lymphoblastoid Interferon Therapy for Chronic HBV Infection

This research investigates the effectiveness of lymphoblastoid interferon therapy in treating chronic hepatitis B virus (HBV) infection. The study compared the outcomes of 12-week and 24-week courses of thrice weekly intramuscular lymphoblastoid interferon in a randomized group of 40 patients. The results revealed a significantly higher clearance rate of HBeAg and HBV-DNA in male patients compared to female patients, with a notable response rate in males that surpasses spontaneous seroconversion rates. The study also identified factors associated with response, such as high AST levels, short duration of disease, and previous history of acute hepatitis.

Potential Gender Differences in HBV Treatment Response

This study suggests that there may be gender-specific differences in response to lymphoblastoid interferon therapy for chronic HBV infection. The study's findings indicate that male patients may have a significantly higher clearance rate of HBeAg and HBV-DNA compared to female patients. This underscores the importance of considering gender as a factor in developing personalized treatment plans for chronic HBV infection.

Navigating the Challenges of Chronic HBV Treatment

This study highlights the complexities of treating chronic HBV infection and the need for tailored treatment approaches. The research underscores the importance of carefully evaluating individual patient factors, such as gender, disease duration, and previous history of acute hepatitis, when determining the most effective treatment strategy. It also emphasizes the importance of ongoing research to develop new and more effective therapies for this challenging condition.

Dr.Camel's Conclusion

This research, like a camel traversing a vast desert of medical knowledge, sheds light on the intricate landscape of chronic HBV infection. The study's findings reveal potential gender-specific differences in treatment response, highlighting the need for personalized care and ongoing research to develop more effective therapies for this complex condition. The journey towards understanding and effectively managing chronic HBV infection continues, and this study serves as a valuable stepping stone in the right direction.

Date :
  1. Date Completed 1987-11-06
  2. Date Revised 2019-08-17
Further Info :

Pubmed ID

3655310

DOI: Digital Object Identifier

10.1016/s0168-8278(87)80061-2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.